Imagine being able to spot cancer early by just taking a simple blood test instead of invasive surgery. For people with a specific genetic risk called Lynch Syndrome, this project creates a high-tech filter that catches tiny cancer signals in the blood. It uses AI to make sure these tests work accurately across different hospitals and countries.
Lynch Syndrome carriers face high cancer risks but lack affordable, non-invasive screening methods, leading to late detection and preventable deaths.
A multi-omic liquid biopsy test utilizing AI and markers (microsatellite instability and metabolomic) to detect early-stage cancers.
If you are a biomarker development firm dealing with low detection rates for early-stage cancers — this project developed a multi-omic liquid biopsy solution that improves the accuracy of detecting precancerous states in Lynch Syndrome carriers.
If you are a private oncology clinic dealing with expensive and invasive screening procedures — this project developed a non-invasive, cost-effective test that allows for easier monitoring of high-risk patients.
If you are an AI medical software company dealing with the need for validated clinical data for cancer screening — this project developed AI-driven identification of cancer traces across diverse healthcare systems.
Based on available project data, the objective is to deliver a cost-effective and affordable test, though specific pricing is not provided.
Yes, the project aims to deliver results that can be rapidly upscaled and adopted across the European Union and globally.
Based on available project data, the project partners with five leading biomarker companies (GNT, MSInsight, MSICare, MSIPlus, and Elypta), but specific licensing terms are not listed.
The project period runs from 2025-05-01 to 2031-04-30.
The project uses AI to ensure the tests are applicable to diverse healthcare systems and includes a socio-economic assessment to align with healthcare needs.
The consortium is highly diversified with 28 partners across 16 countries, blending academic research (9 universities, 9 research institutes) with commercial execution. With a 14% industry ratio and 4 SMEs, the project has a strong foundation for technology transfer, specifically through its direct partnerships with 5 specialized biomarker companies to ensure the final product is market-ready.
Contact Oslo Universitetssykehus HF regarding the PREDI-LYNCH consortium
Contact SciTransfer to connect with the PREDI-LYNCH biomarker partners.
